2015-12-18

White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.

For cancer and other complex diseases, early detection remains the key to successful intervention. In recent years, the growth of large well annotated blood banks has facilitated the discovery of many new biomarkers.  Now, a new White Paper from Immunovia details the efforts to further decipher the wealth of information in serum and translate it into clinically useful tools to diagnose earlier and more accurately than previously possible. The White Papers’ main focus is on pancreatic cancer and how Immunovia is developing IMMray™ PanCan-d, which has the potential to be the first blood based biomarker signature for this devastating disease.

Pancreatic cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 4-6%. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early detection can significantly improve pancreatic cancer patients’ 5-year survival rates from 4-6% to potentially 50-60%.

Immunovia therefore selected pancreatic cancer as their first application for IMMray™, its core antibody biomarker microarray analysis platform. The company has now reached the position where it is performing clinical validation studies required for the commercialization of IMMray™ PanCan-d, as the first blood based test for early diagnosis of pancreatic cancer.

“Based on retrospective studies covering more than 3000 blood samples, we have confirmed that IMMray™ PanCan-d is able to detect pancreatic cancer in all stages, even in stage I and II and has consequently the potential to improve the patients’ overall survival. We have therefore prepared this White Paper to enable healthcare professionals, providers, regulatory bodies and patient groups to understand the full background”, concluded Mats Grahn, CEO Immunovia.

The white paper is available to download on: www.immunovia.com/immray-pancan-d/white-paper


About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. (Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company's Certified Adviser. For more information, please visit www.immunovia.com.


For more information please contact:
Mats Grahn, CEO Immunovia AB
Tel: 46-70-5320230
Email: mats.grahn@immunovia.com




Immunovia AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund